Delivery Order 75N93022D00016-75N93023F00001
Award Date
5/15/23
Potential Completion Date
7/15/25
Potential Value
$2.3M
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Dynport Vaccine Company LLC
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Fort Detrick, MD 21702, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
5
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a cost-plus-fixed-fee delivery order awarded to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corporation, by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH). The $2,191,163 task order is part of the $346 million Early Phase Clinical Trial Units (EPCTU) indefinite-delivery, indefinite-quantity (IDIQ) contract, which funds Phase I clinical trial services. Dynport, a provider of research, development,...
This is a federal contract award with a potential value of $139,426.00, issued by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corp. The contract is a Delivery Order under the "Therapeutics Against Infectious Diseases Phase 1" master IDIQ contract. The award is for a PHASE 1 CLINICAL TRIAL UNIT FOR THERAPEUTICS AGAINST...
This is a $3,860,186.71 cost-plus-fixed-fee task order awarded to Dynport Vaccine Company LLC (DVC), a subsidiary of General Dynamics Corporation, by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services. The task order is for Phase 1 clinical trials of therapeutics against infectious diseases and was issued under the Therapeutics Against Infectious Diseases Phase 1 indefinite-delivery, indefinite-quantity...
This is a delivery order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services (HHS), to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corporation. The $4,120,677 cost-plus-fixed-fee contract is for a Phase 1 clinical trial unit to support the development of therapeutics against infectious diseases. This award is part of the larger Therapeutics Against Infectious Diseases Phase 1 contract vehicle....
This is a delivery order under the "Therapeutics Against Infectious Diseases Phase 1" indefinite delivery, indefinite quantity (IDIQ) contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services. The order, valued at $5,167,891.00, funds a Phase 1 clinical trial unit for therapeutic candidates against infectious diseases. The prime contractor is Dynport Vaccine Company LLC, a subsidiary of General...
This is a Delivery Order under the $3,500.00 Diagnostic Pre-Clinical Services Program IDIQ contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services. The prime contractor is Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corp that provides biopharmaceutical research, development, manufacturing, and testing services. This Delivery Order supports the development of candidate...
This is a cost-plus-fixed-fee delivery order awarded by the Medical Command (MEDCOM) of the U.S. Army to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corporation. The $1,685,156.08 contract is for the Phase 2 clinical trial of the Comprehensive Preventive and Preparedness (CPP) program, which develops medical countermeasures for infectious diseases. The contract is part of Dynport's existing $30 million Preclinical Services for Biopharmaceutical Product Development indefinite...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $3,500 firm fixed price delivery order contract to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corporation, for the Diagnostic Pre-Clinical Services Program. This contract is part of a larger Indefinite Delivery/Indefinite Quantity (IDIQ) contract vehicle that provides funding for development processes needed to bring candidate infectious disease diagnostics to market. Dynport has previous experience...
This is a delivery order award to Dynport Vaccine Company LLC (DVC), a subsidiary of General Dynamics Corp, under the $36 million Diagnostic Pre-Clinical Services Program IDIQ contract with the National Institute of Allergy and Infectious Diseases (NIAID). The task order is for a 7-year period of performance with a ceiling value of $3,500. It does not have a set-aside designation. Under this contract, DVC will provide a range of research, development, manufacturing, and testing services to...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $1.2 million delivery order contract to Dynport Vaccine Company LLC DVC Segment Division for the evaluation of cell lines producing a monoclonal antibody, and production and characterization of a cGMP master cell bank. Dynport Vaccine Company LLC DVC Segment Division, a subsidiary of General Dynamics Corp., will perform this work under its Preclinical Services...